Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its Annual Meeting of Shareholders scheduled for and convened on June 15, 2022 (the...

The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials NEW YORK, June 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a...

The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severity across three efficacy endpoints NEW YORK, May 3, 2022 /PRNewswire/ -- Hoth...

HT-TBI is a novel, point-of-care drug-device combination product under development for acute treatment of secondary brain injury resulting from ischemic stroke and traumatic brain injury NEW YORK,...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 8,235,294 shares of...

Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ for the treatment of Alzheimer's disease NEW YORK, April 12, 2022 /PRNewswire/ -- Hoth...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,235,294 shares of common stock (the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has commenced an underwritten public offering. EF Hutton, division of Benchmark Investments,...

Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours HT-KIT inhibits tumor growth and systemic organ infiltration using both an allograft...

Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the Hoth Therapeutics Pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer's Disease Therapeutic NEW YORK,

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced development updates for its cancer therapeutic, HT-KIT after receiving Orphan Drug Designation...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) designated HT-KIT, a new molecular entity, as an...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced an abstract submission to present the preclinical Alzheimer's disease mouse model data of...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that enrollment...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has signed a Sponsored Research Agreement with North Carolina State University ("NC...

Hoth Therapeutics, Inc., (NASDAQ: HOTH) a patient focused biopharmaceutical company, announced today that it has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1b...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety data from the first cohort of...

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical trial of the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model. The...

NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive...

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will share positive results from a preclinical trial during its shareholder...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today plans to host a virtual information session on its pipeline product, HT-KIT, a new molecular...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will be an exhibitor at the American Society of Clinical Oncology (ASCO) Annual...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today it plans to host a virtual information session on its pipeline product, HT-005 Z-Pods™, a...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its sponsored research agreement with Virginia Commonwealth University (VCU) for a potential...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibited highly positive results in humanized...

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed the formulation for HT-001, a...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials ("Worldwide"), a full-service Contract Research...

Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a notice of allowance for a patent...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002, a...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the Benzinga Biotech Small Cap Conference...

Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced an exclusive interview featuring Robb Knie, CEO, airing on The RedChip Money...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a Research Agreement with the University of Cincinnati Research Institute ("UCRI") to perform...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed an agreement with REPROCELL Ltd., a contract research organization (CRO), providing a unique...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced the closing of its previously announced private placement of common stock and...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced that it has entered into a definitive agreement with certain institutional and...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today provided an update on preclinical study on HT-002 for the prevention and/or treatment of...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its licensing agreement from North Carolina State University ("NC State") to include the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its investor relations efforts. RedChip is the leader...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has filed a provisional patent application with the United States Patent and Trademark Office for the use of...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it will be presenting at the upcoming the Diamond Equity Research Growth Invitational virtual investor...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member, Michael Peter, Ph.D., published a whitepaper in bioRxiv regarding...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed an agreement with Camargo Pharmaceutical Services to facilitate the writing and submission...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel therapeutics targeting dermatological, COVID-19 and...

Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company, today announced extending a research collaboration agreement with Weill Cornell Medicine to continue...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), ("Hoth" or the "Company"), a biopharmaceutical company, today announced the addition of Mario Lacouture, M.D. to the Company's Scientific Advisory Board....

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the Pre-IND meeting requested on 22 December 2020 for HT-001 with the U.S. Food and Drug Administration (FDA)...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001, a topical formulation...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to...

Hoth (NASDAQ: HOTH) has a partnership agreement with Zylö Therapeutics Inc.,to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence the first cohort of the Phase...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the novel COVID-19 products currently being...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S....

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement ("SRA") with the George Washington University ("GW")...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced Dr. Stefanie Johns, who has agreed to join Hoth and serve as its Chief Scientific Officer, is scheduled to...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective September 2020....

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Chief Executive Officer, Robb Knie, is scheduled to present at the following investor conferences in...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today is providing shareholders with a update on its COVID-19 initiatives including vaccine and real-time, breath-based mobile...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing the intellectual property rights relating to the development of a medical device that has the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire the rights to VNLG-152, a...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 therapeutic, Michael H. Peters,...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today provided an update on its pipeline of therapeutics including six compounds in various stages of clinical development,...

Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of 1,818,182...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters is the inventor...

Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at...

Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virginia Commonwealth University ("VCU") for a...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform, a...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc ("Zylö"). Mr. Robb Knie, Chief Executive...

Hoth Therapeutics, Inc. (Nasdaq: HOTH) announced today that Voltron Therapeutics, Inc has selected the peptides required to complete the structure of HaloVax for development and progression into...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m....

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m....

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley, to its Board of Directors....